Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.34 |
---|---|
High | 2.38 |
Low | 2.08 |
Bid | 2.11 |
Offer | 2.19 |
Previous close | 2.30 |
Average volume | 79.71k |
---|---|
Shares outstanding | 12.05m |
Free float | 7.59m |
P/E (TTM) | -- |
Market cap | 27.73m USD |
EPS (TTM) | -4.11 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
- HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
- HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
- HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
- HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
- HOOKIPA Pharma Announces Board of Directors Changes
- HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
- HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
- HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
More ▼